Dexcom (DXCM)

Executive Summary

Dexcom, Inc. is a leading continuous glucose monitoring (CGM) company with over 25 years of innovation, serving Type 1, Type 2, and gestational diabetes patients. Its flagship G7 CGM system and recently launched over-the-counter Stelo biosensor for metabolic health have expanded its addressable market. With a $24.44 billion market cap, Dexcom is the most widely covered CGM brand globally and the preferred solution for Medicare Advantage patients. The company's strong brand and technological edge position it well for sustained growth, though competition from Abbott's Libre and emerging players remains a challenge. Looking ahead, Dexcom's growth is fueled by expanding CGM adoption in Type 2 diabetes, the success of Stelo in the direct-to-consumer metabolic health market, and potential label expansions. The company is also investing in next-generation sensors and integration with insulin pumps. Despite near-term headwinds from pricing pressure and a maturing U.S. market, international expansion and new indications offer substantial upside. Dexcom's robust pipeline and market leadership underpin a favorable outlook, with the company expected to maintain its trajectory through product innovation and strategic market penetration.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation CGM sensor (G8 or equivalent) in key markets80% success
• Q1 2027FDA clearance for expanded Stelo OTC indications (e.g., pre-diabetes)65% success
• Q4 2026New Medicare coverage expansion for Type 2 diabetes patients on non-intensive insulin therapy70% success